MYELOPROLIFERATIVE NEOPLASM
Clinical trials for MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control TerminatedThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Matched conditions: MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Blood cancer drug fails to show promise in Post-Transplant trial
Disease control TerminatedThis early-phase trial tested the drug fedratinib (Inrebic) as a maintenance therapy to prevent relapse in people with myeloproliferative neoplasms after a stem cell transplant. Only 12 participants were enrolled before the study was terminated. The goal was to find a safe dose a…
Matched conditions: MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC